Erythema

Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021

Retrieved on: 
Wednesday, September 15, 2021
Bruise, Patient, Bupivacaine, Peri, Private Securities Litigation Reform Act, Tenderness, Safety, Liver disease, Adoption, Inflammation, Red, Osteoarthritis, Analgesic, Nasdaq, Cryoglobulinemia, Child, Vomiting, Nervous system, Paroxysmal cold hemoglobinuria, Joint, Adult, Spine, Annual report, Industry, Vaccine, Vein, Swelling, Nausea, Pregnancy, Growth, Time-invariant system, Allergy, COVID-19, Molecule, Erythema, Cold urticaria, Fever, Ice, Pain, GLOBE, Freezing, Knee, Fasciculation, Time, SEC, Constipation, Sensation, Edema, Animal, Birth control, Pharmaceutical industry

PARSIPPANY, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales. EXPAREL® (bupivacaine liposome injectable suspension) net product sales increased 15 percent to $41.4 million for the month of August 2021, compared with $36.1 million for the prior year. Net product sales of iovera° increased 13 percent to $0.9 million for the month of August 2021, compared with $0.8 million for the prior year. EXPAREL average daily sales for the month of August 2021 were 109 percent of August 2020. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. EXPAREL selling days were 22 in August 2021 and 21 in August 2020.

Key Points: 
  • PARSIPPANY, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales.
  • EXPAREL (bupivacaine liposome injectable suspension) net product sales increased 15 percent to $41.4 million for the month of August 2021, compared with $36.1 million for the prior year.
  • Net product sales of iovera increased 13 percent to $0.9 million for the month of August 2021, compared with $0.8 million for the prior year.
  • To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19.

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction

Retrieved on: 
Thursday, September 9, 2021

Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

Key Points: 
  • Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.
  • Allergic (hypersensitivity) reactions.Symptomsofseriousallergicreactionsto JARDIANCE mayinclude:
    If you have anyof these symptoms,stoptakingJARDIANCEandcontactyourhealthcare providerorgo to the nearestemergencyroomrightaway.
  • Before taking JARDIANCE, tellyourhealthcare providerabout all of your medical conditions, including ifyou:
    are going to have surgery.
  • Clinical trials have been initiated to evaluate the impact of Jardiance on people living with heart failure or chronic kidney disease.

UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Retrieved on: 
Thursday, September 9, 2021
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Atopic Dermatitis, CIBINQO®, Pfizer: Breakthroughs That Change Patients’ Lives, ATOPIC DERMATITIS, CIBINQO®, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

We welcome the MHRAs authorization of abrocitinib to treat people with moderate to severe atopic dermatitis.

Key Points: 
  • We welcome the MHRAs authorization of abrocitinib to treat people with moderate to severe atopic dermatitis.
  • Last year, abrocitinib received a Promising Innovative Medicine (PIM) designation from the MHRA.
  • This enabled healthcare professionals to prescribe the treatment prior to marketing authorization, based on clinical factors for patients with a clear unmet need.
  • Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis.

Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis

Retrieved on: 
Monday, August 30, 2021
Biotechnology, Pharmaceutical, Health, Janus, III, JADE, Atopic dermatitis, Inflammation, Twitter, Death, Week, U.S. Securities and Exchange Commission, PFE, Skin, Intracranial hemorrhage, EASI, Science, TSLP, Research, Food, Psoriasis Area and Severity Index, Doctor of Philosophy, Cancer, Inc., NYSE, Abrocitinib, Risk, Clinical trial, Erythema, Immunology, Adult, Fortis Healthcare, European Medicines Agency, Patient, AD, LinkedIn, Vaccine, Dermatitis, MACE, VTE, YouTube, FDA, Facebook, News, Arrest, COVID-19, JAK, JAK1, Thrombosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Abrocitinib, Atopic Dermatitis, Pfizer: Breakthroughs That Change Patients’ Lives, ABROCITINIB, ATOPIC DERMATITIS, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

The head-to-head study was designed to directly compare the efficacy of abrocitinib 200mg versus dupilumab 300mg, in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).

Key Points: 
  • The head-to-head study was designed to directly compare the efficacy of abrocitinib 200mg versus dupilumab 300mg, in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).
  • The study will allow assessment of any difference in efficacy that may persist at month 6 of treatment.
  • The study is part of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program for abrocitinib.
  • Full results from JADE DARE will be submitted for presentation at a future scientific meeting and publication in a medical journal.

Lumenis Raises The Bar For Aesthetic Outcomes With SmoothGlo™

Retrieved on: 
Tuesday, August 17, 2021
Stellar, Industry, Contraindication, Red, Genetically modified bacteria, Ageing, Edema, Pain, Instagram, Burn, City, Intense, Skin, Pimple, Medicine, Frequency, Blister, Skin care, Social media, Laser, Acne, RF, Awareness, Marketing, The Real Housewives of Beverly Hills, League of Legends Pro League, Aesthetics, Asia, Multimedia, Surgery, Artificial cardiac pacemaker, Erythema, Scar, IPL, Patient, Solution, Transience, Swelling, View, Pigment, Medical device, Pharmaceutical industry

LOS ANGELES, Aug. 17, 2021 /PRNewswire/ -- Lumenis, Ltd., the world's largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications is proud to announce the launch of SmoothGlo, a novel, nonsurgical approach to addressing the three most visible signs of aging – tone, texture, and volume. SmoothGlo's impressive results are achieved via leveraging the capabilities of Stellar M22™ IPL and Legend Pro™ VoluDerm™ technologies, long-considered best-in-class throughout the industry.

Key Points: 
  • Both celebrities loved the quick, comfortable treatment and joined the SmoothGlo bandwagon as celebrity spokespersons.
  • Kyle and Jade will be sharing their SmoothGlo experience with their immense social media following as they complete their treatment regimen.
  • Each SmoothGlo vehicle earns thousands of impressions per month and sends patients to a certified SmoothGlo provider.
  • All certified SmoothGlo providers enjoy discounts, exclusive marketing materials, and the immense benefits of support by two of today's most popular television personalities.

Global Netherton Syndrome Market Insight, Epidemiology and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 12, 2021
Pharmaceutical, Health, Clinical Trials, Lists of people executed in the United States, SME, Light, Comprehension, PESTLE, Table, NS, Population, Syndrome, News, SWOT, Tacrolimus, Disease, OTC, Hyperkinesia, Pimecrolimus, Porter's five forces analysis, Risk, Growth–share matrix, Acquisition, Toxicity, UVA, Netherton syndrome, Skin, Patient, Hair, Technology, Gaps, Erythema, Plasma protein binding, Therapy, Protease, Management, Pharmaceutical industry, Cosmetics, Marketing

The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical and forecasted Netherton Syndrome epidemiology segmented as the prevalent population of Netherton Syndrome and severity-specific cases of Netherton Syndrome.
  • The epidemiology segment also provides the Netherton Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021

Retrieved on: 
Tuesday, August 10, 2021
Swelling, Cold urticaria, Joint, Spine, Osteoarthritis, Vein, Patient, Private Securities Litigation Reform Act, Analgesic, COVID-19, Liver disease, Molecule, Goal, Nervous system, Paroxysmal cold hemoglobinuria, Red, Bupivacaine, Nasdaq, Cryoglobulinemia, Fever, Central nervous system, Vomiting, Safety, Knee, Freezing, Growth, SEC, Time, Nausea, Edema, Ice, Erythema, Pregnancy, Industry, Sensation, GLOBE, Constipation, Bruise, Annual report, Child, Inflammation, Tenderness, Fasciculation, Peri, Pain, Vaccine, Time-invariant system, Allergy, Animal, Pharmaceutical industry

PARSIPPANY, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL (bupivacaine liposome injectable suspension) and iovera of $40.9 million and $1.0 million, respectively, for the month of July 2021.

Key Points: 
  • PARSIPPANY, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL (bupivacaine liposome injectable suspension) and iovera of $40.9 million and $1.0 million, respectively, for the month of July 2021.
  • EXPAREL average daily sales for the month of July 2021 were 117 percent of July 2020.
  • To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19.
  • The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period.

Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine

Retrieved on: 
Monday, August 9, 2021
Infectious Diseases, Biotechnology, Genetics, Health, Erythema, Headache, World Health Organization, Emergency Use Authorization, Chills, RNA transfection, Degenerative disease, Pregnancy, Exercise, U.S. Securities and Exchange Commission, Pericarditis, Adolescence, TGA, Infection, Private Securities Litigation Reform Act, COVID-19, Vaccine, Government, World, Pain, Korea Disease Control and Prevention Agency, RNA, Therapy, Biotechnology, Fever, Swelling, Annual report, Vaccination, Person, Center, Allergy, Arthralgia, Vaccine-associated enhanced respiratory disease, Fatigue, Therapeutic Goods Administration, Science, Ageing, EUL, SEC, Myocarditis, Anaphylaxis, Health care, MRNA, History, Nasdaq, Myalgia, EUA, Clinical trial, Immunodeficiency, Milk, Intention, VAERS, CDC, WHO, Pharmaceutical industry

The TGA continues to evaluate an application for provisional registration of Modernas COVID-19 vaccine for use in adolescents aged 12 to 18 years.

Key Points: 
  • The TGA continues to evaluate an application for provisional registration of Modernas COVID-19 vaccine for use in adolescents aged 12 to 18 years.
  • The Therapeutic Goods Administration has granted provisional registration to the COVID-19 Vaccine Moderna in Australia for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.
  • Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.
  • The CDC has published clinical considerations relevant to myocarditis and pericarditis associated with administration of the Moderna COVID-19 Vaccine ( https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditi... ).

FDA Approves New Treatment for Pompe Disease

Retrieved on: 
Friday, August 6, 2021
Smokeless tobacco, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Fatigue, Lists of diseases, Cell, Genzyme, Food, Dizziness, Safety, Public health, Nausea, Glycogen, Itch, Vaccine, Arthralgia, Degenerative disease, Pediatrics, Patient, Center, Disease, Diarrhea, Center for Drug Evaluation and Research, Needle, Vomiting, Priority review, Thermoregulation, Heart failure, Myalgia, Erythema, Multimedia, FDA, Research, Reproductive medicine, Breathe Me, Paresthesia, Chills, Dietary supplement, Fast Track, Risk, Hives, Cosmetics, Enzyme replacement therapy, China Biologic Products, Death, Glycogen storage disease type II, Anaphylaxis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Headache, Animal, Muscle weakness, Volume overload, Pharmaceutical industry

Patients with Pompe disease have an enzyme deficiency that leads to the accumulation of a complex sugar, called glycogen, in skeletal and heart muscles, which cause muscle weakness and premature death from respiratory or heart failure.

Key Points: 
  • Patients with Pompe disease have an enzyme deficiency that leads to the accumulation of a complex sugar, called glycogen, in skeletal and heart muscles, which cause muscle weakness and premature death from respiratory or heart failure.
  • "Pompe disease is a rare genetic disease that causes premature death and has a debilitating effect on people's lives," said Janet Maynard, M.D., deputy director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA's Center for Drug Evaluation and Research.
  • "Today's approval brings patients with Pompe disease another enzyme replacement therapy option for this rare disease.The FDA will continue to work with stakeholders to advance the development of additional new, effective and safe therapies for rare diseases, including Pompe disease."
  • The effectiveness of Nexviazyme for the treatment of Pompe disease was demonstrated in a study of 100 patients who were randomized to take Nexviazyme or another FDA-approved enzyme replacement therapy for Pompe disease.